BiotechTube
BioLegend

BioLegend

San Diego, United States· Est.
biolegend.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioLegend is a privately held, revenue-generating life sciences reagent company that has established itself as a key supplier to the global biomedical research market. The company's core strength lies in its deep expertise in immunology and its vertically integrated model, which encompasses in-house antibody development, conjugation, validation, and manufacturing. By focusing on high-quality, well-characterized reagents and a customer-centric approach, BioLegend has built a strong brand reputation among researchers. Its strategic acquisition by PerkinElmer in 2022 has provided significant resources for scaling operations and expanding its technological and geographic reach.

Antibodies

Technology Platform

Integrated platform for antibody development, conjugation, validation, and manufacturing, coupled with multiplex immunoassay (LEGENDplex) and cell isolation technologies.

Funding History

1
UndisclosedUndisclosed

Opportunities

Capitalizing on the growth in immuno-oncology, spatial biology, and cell/gene therapy research through expanded reagent and assay portfolios.
Leveraging PerkinElmer's global distribution to accelerate growth in Asia-Pacific markets.
Exploring adjacencies in diagnostic component supply.

Risk Factors

Integration challenges following the PerkinElmer acquisition could disrupt culture and operations.
Faces intense competition in the crowded life science reagents market, with constant pressure on pricing and innovation.
Research funding cycles and supply chain vulnerabilities pose external risks to stable demand and cost structure.

Competitive Landscape

BioLegend competes in a fragmented but concentrated market with major players like Thermo Fisher Scientific, Abcam (now part of Danaher), Bio-Rad, and BD Biosciences. Its differentiation is built on high-quality, well-validated antibodies primarily in immunology, strong technical support, and a scientist-centric brand. The acquisition by PerkinElmer elevates its competitive scale against the largest integrated players.

More companies in Biologics / Biosimilars →More companies in United States →